角膜專題演講會 | Cornea Symposium
13 Dec 2025
14:30
17:30
701D
| Time | Session |
|---|---|
|
14:30
16:00
|
701D
|
|
14:30
14:50
|
|
|
14:50
15:10
|
David HuangUnited States
Speaker
OCT/OCTA Application in the Anterior SegmentOptical coherence tomography (OCT) applications in the anterior segment have lagged retinal
imaging because of the wider area and deeper structures that need to be covered, including the
cornea, anterior chamber, and crystalline lens. With recent advances in the speed and depth
range of both spectral-domain and swept-source OCT has finally hit the mainstream with many
products reaching the market in the past 5 years. Compared to Placido-disc and Scheimpflug
slit-scanning technologies, OCT offers higher depth resolution and the ability to map epithelial
thickness as well as pachymetry, anterior topography, and posterior topography. This lecture will
describe how this can be used to detect and differentiate among the major classes of corneal
diseases. Other topics that will be covered include wide-field OCT for corneoscleral topography,
OCT microscopy to see cells and pathogens, OCT biometry for intraocular lens calculations, and
OCT angiography for the evaluation of iris and ocular surface tumors.Seeing Small and Aiming Big: the Development and Clinical Impact of Optical Coherence TomographyOptical coherence tomography (OCT) is a technology invented in 1991 to image small critical tissue
structures with micrometer resolution. It is widely used in eye and coronary heart diseases. I will
tell the story of OCT’s initial conception from the inventor’s perspective along with an account of
the rapid pace of development that made OCT a clinical reality. The biggest applications of OCT in
the management of eye diseases will be shown. Recent advances that enable OCT to advance
beyond the imaging of tissue structure to the detection of blood flow and photoreceptor function
will be described. The roles of academia, industry, and government agencies in the clinical
translation of OCT will be highlighted.
|
|
15:10
15:30
|
陳偉勵 Wei-Li ChenTaiwan
Speaker
Using AS-OCT with epithelial thickness mapping and a self-developed stromal thickness map to detect early corneal ectasia and prevent postoperative ectasia following refractive surgeryEarly detection of subclinical corneal ectasia remains one of the most critical challenges in managing ophthalmic diseases and performing modern corneal refractive surgery. Advances in anterior segment optical coherence tomography (AS-OCT) have enabled highly detailed assessment of corneal microstructure, particularly through epithelial thickness mapping, which often reveals subtle compensatory remodeling before stromal abnormalities become clinically apparent. In this study and clinical application series, we introduce—and precisely apply—epithelial thickness mapping together with our team’s newly developed **corneal stromal thickness difference map** to further enhance the sensitivity of ectasia screening.
This lecture summarizes our team’s recently published work as well as upcoming research, with a focus on how these innovative imaging approaches allow for **early detection of corneal ectasia**, even before topographic changes emerge. Our difference map quantifies disparities between epithelial masking patterns and stromal surface alterations, enabling clinicians to identify early biomechanical instability that is often invisible on conventional topography or tomography.
Through this presentation, attendees will gain a deeper understanding of the latest clinical applications of AS-OCT epithelial mapping and how these advanced tools can be integrated into routine practice to more effectively detect, manage, and prevent hidden or subclinical corneal ectasia. These innovations provide additional structural insight that supports more accurate refractive surgical planning and contributes to improved long-term corneal stability.
|
|
15:30
15:45
|
|
|
15:45
16:00
|
|
|
16:00
17:30
|
701D
|
|
16:00
16:15
|
Shigeru KinoshitaJapan
Speaker
Toward Corneal Regenerative MedicineSevere ocular surface and corneal disorders—including Stevens-Johnson syndrome, chemical injury, ocular cicatricial pemphigoid, Fuchs endothelial corneal dystrophy (FECD), and advanced corneal endothelial failure—remain difficult to manage. Recent advances in ocular surface biology and regenerative medicine have enabled the development of transplantable epithelial sheets, such as allogeneic/autologous corneal epithelial stem-cell sheets, autologous cultivated oral mucosal epithelial sheets (COMET), and iPSC-derived corneal epithelial sheets, some of which have received regulatory approval from the EMA and PMDA.
Corneal endothelial dysfunction is also being addressed through regenerative medicine approaches. The transplantation (via injection) of mature, differentiated cultured human corneal endothelial cells (CHCEC) combined with a ROCK inhibitor into the anterior chamber has demonstrated favorable efficacy and safety, leading to PMDA approval in 2023 and subsequent clinical application in Japan beginning in September 2024. In addition, ROCK-inhibitor eye drops have demonstrated potential in treating early-stage endothelial dysfunction in FECD.
Continued progress in corneal regenerative therapies promises to advance global regulatory acceptance and contribute meaningfully to the prevention of blindness worldwide.
|
|
16:15
16:45
|
Shigeru KinoshitaJapan
Speaker
Toward Corneal Regenerative MedicineSevere ocular surface and corneal disorders—including Stevens-Johnson syndrome, chemical injury, ocular cicatricial pemphigoid, Fuchs endothelial corneal dystrophy (FECD), and advanced corneal endothelial failure—remain difficult to manage. Recent advances in ocular surface biology and regenerative medicine have enabled the development of transplantable epithelial sheets, such as allogeneic/autologous corneal epithelial stem-cell sheets, autologous cultivated oral mucosal epithelial sheets (COMET), and iPSC-derived corneal epithelial sheets, some of which have received regulatory approval from the EMA and PMDA.
Corneal endothelial dysfunction is also being addressed through regenerative medicine approaches. The transplantation (via injection) of mature, differentiated cultured human corneal endothelial cells (CHCEC) combined with a ROCK inhibitor into the anterior chamber has demonstrated favorable efficacy and safety, leading to PMDA approval in 2023 and subsequent clinical application in Japan beginning in September 2024. In addition, ROCK-inhibitor eye drops have demonstrated potential in treating early-stage endothelial dysfunction in FECD.
Continued progress in corneal regenerative therapies promises to advance global regulatory acceptance and contribute meaningfully to the prevention of blindness worldwide.
|
|
16:45
17:00
|
馬惠康 David Hui-Kang MaTaiwan
Speaker
Cultivated Oral/Nasal Mucosal Epithelial Sheets for Ocular Surface Reconstruction in TaiwanBackground
To investigate the in vivo epithelial phenotypes of cultivated nasal mucosal epithelial cell (CUNMEC) sheets generated by a microspheroidal suspension culture technique.
Methods
Human nasal mucosal tissues were obtained during DCR. The tissues were digested with 2 mg/mL collagenase A, then the cell aggregates were seeded onto a de-epithelialized AM and cultivated for 2 weeks. The CUNMEC sheets were then transplanted into New Zealand albino rabbits. The animals were subjected to immunosuppression for two weeks and then sacrificed. The samples were subjected to light and electron microscopy (EM) and immunoconfocal microscopy examinations.
Results
The presence of CUNMECs in rabbit eyes was confirmed by anti-human cytoplasmic
antibody staining. Keratins 3, 4, and 13 were positively expressed in the suprabasal
region, whereas p63 expression was observed only in the basal layer. Transmission
EM revealed stratified epithelium with the formation of desmosomes and
hemidesmosomes. Scanning EM revealed a cobble stone-like epithelial surface
without cilia formation. α-Tubulin, a major component of cilia, was expressed only in
the apical region of the nasal mucosa and showed diffuse cytoplasmic staining in the
CUNMEC sheets. ZO-1, a component of tight junctions, was expressed in the apical
region of the nasal mucosa and was expressed at intercellular borders in CUNMECs.
Conclusion
Following transplantation, the CUNMEC sheet presented a stratified epithelial layer
containing GCs but without cilia and expressed progenitor cell markers, which are
morphologically similar to those of ocular surface epithelia and may have the potential to function as a surrogate epithelium for ocular surface reconstruction, especially in dry eye conditions.
|
|
17:00
17:15
|
|
|
17:15
17:30
|